Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Details : MC-1 (pyridoxal phosphate) is a naturally occuring purinergic receptor antagonist, which is being evaluated for the treatment of Pyridox(am)Ine 5'-Phosphate Oxidase (PNPO) Deficiency.
Brand Name : MC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 23, 2024
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FDA provides complete approval to enroll patients in its pivotal clinical trial to evaluate "MC-1" (a naturally occurring metabolite of pyridoxine) for treatment of a rare pediatric disease called pyridox(am)ine 5′-phosphate oxidase deficiency.
Brand Name : MC-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2023
Lead Product(s) : Pyridoxal Phosphate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?